Cyclacel Pharmaceuticals (NASDAQ:BGMS) Issues Quarterly Earnings Results

Posted by Brenda Bartman on Aug 16th, 2026

Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) posted its earnings results on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.34 million for the quarter.

Cyclacel Pharmaceuticals Stock Down 1.1%

Shares of BGMS stock opened at $0.92 on Friday. Cyclacel Pharmaceuticals has a 12 month low of $0.57 and a 12 month high of $9.40. The stock has a 50 day moving average of $0.88 and a 200-day moving average of $0.97. The firm has a market cap of $5.05 million, a PE ratio of -0.25 and a beta of -0.38.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Get Our Latest Stock Report on Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Company Profile

(Get Free Report)

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.